Saniona: Major breakthrough as SAN711 is outlicensed to Acadia - Redeye

Redeye briefly comments on the positive news that Saniona has outlicensed SAN711 to Acadia in neurological diseases. We see this as a major breakthrough for the company that should open a lot of possibilities for the company to advance and broaden its pipeline. We give our initial comment and will return after the Q3 report with a more extensive take.

Länk till analysen i sin helhet: https://www.redeye.se/research/1061305/saniona-major-breakthrough-as-san711-is-outlicensed-to-acadia?utm_source=finwire&utm_medium=RSS